¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"transfer host"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • magnetization transfer pulse
    ÀÚ±âÈ­Àü´ÞÆÄ
  • magnetization transfer ratio
    ÀÚ±âÈ­Àü´ÞºñÀ²
  • passive transfer
    ¼öµ¿Àü´Þ
  • resistance transfer factor
    ³»¼ºÀü´ÞÀÎÀÚ
  • tendon transfer
    ÈûÁÙÀüÀÌ(¼ú), °ÇÀüÀÌ(¼ú)
  • zygote intrafallopian transfer
    Á¢ÇÕÀÚÀڱðü³»À̽Ä, Á¢ÇÕüÀڱðü³»Àü´Þ
  • accidental host
    ¿ì¿¬¼÷ÁÖ
  • definitive host
    Á¾¼÷ÁÖ
  • final host
    Á¾¼÷ÁÖ
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • host
    ¼÷ÁÖ
  • host adaptation
    ¼÷ÁÖÀûÀÀ
  • host attribute
    ¼÷ÁÖ¼Ó¼º
  • host defense
    ¼÷ÁÖ¹æ¾î
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • host preference
    ¼÷ÁÖ¼±È£
  • host range
    ¼÷ÁÖ¹üÀ§
  • host selection
    ¼÷ÁÖ¼±ÅÃ
  • host specificity
    ¼÷ÁÖÆ¯À̼º
  • host susceptibility
    ¼÷ÁÖ°¨¼ö¼º
  • host range mutation
    ¼÷ÁÖ¹üÀ§º¯ÀÌ, ¼÷ÁÖ¿ªº¯ÀÌ
  • host-controlled modification
    ¼÷ÁÖÁ¶Àý¼ö½Ä
  • host-parasite relationship
    ¼÷ÁÖ±â»ýü»óÈ£°ü°è
  • host-parasite specificity
    ¼÷ÁÖ±â»ýÃæÆ¯À̼º
  • host-range mutant
    ¼÷ÁÖ¹üÀ§º¯ÀÌÁÖ, ¼÷ÁÖ¿ªµ¹¿¬º¯ÀÌü
  • intermediate host
    Áß°£¼÷ÁÖ
  • natural host
    ÀÚ¿¬¼÷ÁÖ
  • paratenic host
    ¿¬Àå¼÷ÁÖ
  • primary host
    (¢¡definitive host) ÃÖÁ¾¼÷ÁÖ
  • reservoir host
    º¸À¯¼÷ÁÖ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Hfr mediated gene transfer
    °íºóµµÀçÁ¶ÇÕ¼¼Æ÷¸Å°³ À¯ÀüÀÚÀüÀÌ
  • RNA, transfer
    Àü´ÞRNA, tRNA
  • ZIFT(zygote intrafallopian transfer)
    Á¢ÇÕÀÚ ³­°ü³» À̽Ä
  • afterimage transfer test
    ÀÜ»óÀüÀ̰˻ç
  • antibody transfer
    Ç×üÀÌÀÔ(¡­ì¹ìý).
  • heat transfer =h. transmission
    ¿­Àü´Þ(æðîîÓ¹).
  • heat transfer =h. transmission
    ¿­Àü´Þ(ËçËøËÀ).
  • heat transfer rate
    ¿­Àü´Þ·ü(¡­ëÒ).
  • heat transfer rate
    ¿­Àü´Þ·ü(ÊÙËô).
  • high linear energy transfer radiation
    °í¼±Çü¿¡³ÊÁöÀüÀ̹æ»ç¼±
  • placenta transfer
    ŹÝÀüÀÌ, ŹÝÅë°ú
  • placental transfer
    ŹÝÀ̵¿.
  • placental transfer
    ŹÝÀ̵¿(÷ÃÚïì¹ÔÑ)
  • radiation,linear energy transfer (let)
    ¼±»ó¿¡³ÊÁöÀüȯ(àÊß¾¡­ï®üµ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • host controlled variation
    ¼÷ÁÖÀÇÁ¸(±ÔÁ¦)º¯ÀÌ.
  • host defense
    ¼÷ÁÖ¹æ¾î
  • host factor
    ¼÷ÁÖÀÎÀÚ
  • host integration factor (HIF)
    ¼÷ÁÖÅëÇÕÀÎÀÚ
  • host range
    ¼÷ÁÖ¹üÀ§, ¼÷ÁÖ¿ª
  • host range mutation
    ¼÷ÁÖ¿ªº¯ÀÌ
  • host-controlled modification
    ¼÷ÁÖÁ¶Àý¼ö½Ä
  • host-parasite relationship
    ¼÷ÁÖ-±â»ýü »óÈ£°ü°è
  • host-parasite relationship
    ¼÷ÁÖ±â»ýü°ü°è
  • host-parasite relationships
    ¼÷ÁÖ ±â»ýÃæ(»ó°ü) °ü°è
  • host-range mutant
    ¼÷ÁÖ¹üÀ§º¯ÀÌÁÖ
  • intermediate host
    Áß°£¼÷ÁÖ
  • mutant, host range
    ¼÷ÁÖ¿ª µ¹¿¬º¯ÀÌÁÖ
  • pneumonia,in immunocompromised host
    ¸é¿ª±â´ÉÀúÇϼ÷ÁÖÀÇ (Øóæ¹Ñ¦Òöî¸ù»âÖñ«¡­)
  • relation[ship], host-parasite
    ¼÷ÁÖ-±â»ýü »óÈ£°ü°è
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • natural host
    ÀÚ¿¬°¨¿°¼÷ÁÖ
  • principal host
    ÁÖ¼÷ÁÖ
  • reservoir host
    º¸À¯¼÷ÁÖ
  • second intermediate host
    Á¦ÀÌÁß°£¼÷ÁÖ
  • susceptible host
    °¨¼ö¼º¼÷ÁÖ
  • transport host
    ¿î¹Ý¼÷ÁÖ
  • unnatural host
    ºñÈ£Àû¼÷ÁÖ
  • vector host
    ¸Å°³¼÷ÁÖ
  • vicarious host
    ´ë¸®¼÷ÁÖ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cholesterol ester transfer protein
    ÄÝ·¹½ºÅ×·Ñ¿¡½ºÅÍ ÀüÀ̴ܹéÁú(ï®ì¹Ó±ÛÜòõ)
  • electron transfer chain
    ÀüÀÚÀü´Þ(ï³í­îîÓ¹) »ç½½
  • electron transfer flavoprotein
    ÀüÀÚÀü´Þ(ï³í­îîÓ¹) Ç÷¹À̺¸´Ü¹éÁú(Ó±ÛÜòõ)
  • electron transfer potential
    ÀüÀÚÀü´Þ ÀüÀ§(ï³í­îîÓ¹ï³êÈ)
  • electron transfer protein
    ÀüÀÚÀü´Þ ´Ü¹éÁú(ï³í­îîÓ¹Ó±ÛÜòõ)
  • electron transfer system
    ÀüÀÚÀü´Þ(ï³í­îîÓ¹) ½Ã½ºÅÛ
  • energy transfer
    ¿¡³ÊÁö ÀüÀÌ(ï®ì¹)
  • exciton transfer
    ¿¢½ÃÅæ ÀüÀÌ(ï®ì¹)
  • filter affinity transfer
    °Å¸£°Ô ģȭÀüÀÌ(öÑûúï®ì¹)
  • group transfer reaction
    ¿øÀÚ´Ü ÀüÀÌ ¹ÝÀÀ(ê«í­Ó¥ï®ì¹Úãëë)
  • group transfer potential
    ¿øÀÚ´Ü ÀüÀÌ ÀüÀ§(ê«í­Ó¥ï®ì¹Úãëë)
  • infectious transfer
    °¨¿°¼º ÀÌÀü(Êïæøàõì¹ï®)
  • initiator transfer RNA
    °³½Ã(ËÒã·) Àü´Þ(îîÓ¹)RNA
  • isoacceptor transfer RNA
    µ¿Á¾¼ö³³Ã¼(ÔÒðúáôÒ¡ô÷) ÀüÀÌ(ï®ì¹)RNA
  • linear energy transfer
    ¼±Çü(àÊû¡) ¿¡³ÊÁöÀüÀÌ(ï®ì¹)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
G vs HD graft versus host disease
HCR heme-controlled repressor; host-cell reactivation; hysterical conversion reaction
HDF host defense factor; human diploid fibroblast
HOST hypo-osmotic shock treatment
hr hairless [mouse]; host-range [mutant]; hour
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
GvHR Graft v Host Reaction
GvH Graft versus Host
GVH Graft versus host reaction
GVHR Graft versus host reaction
GVHD Graft vs host disease
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • transcapillary transfer
    ¸ð¼¼°ü À̵¿
  • transfer
    Àü´Þ, ÀüÀÌ, Àü¼ÛÇÏ´Ù
    ÇÑ Àå¼Ò¿¡¼­ ´Ù¸¥ Àå¼Ò·Î ¾î¶² ¹°ÁúÀÌ À̵¿µÇ´Â °Í.
  • transfer coping
    ±Ý¼ÓÁ¦ °ñ¹«, Áö´ëÄ¡ ¸ðÇü °íÁ¤¿ë °ñ¹«, ÀüÀÌ¿ë ÄÚÇÎ
    ÀÎ»ó¿¡ Ä¡ÇüÀ» À§Ä¡½Ã۴µ¥ »ç¿ëÇÏ´Â ±Ý¼Ó ¶Ç´Â ¾ÆÅ©¸± ¼öÁö·Î µÈ ÇǺ¹¹°À̳ª ca
  • transfer factor
    Àü´Þ ÀÎÀÚ, ÀüÀÌ ¿äÀÎ
  • transfer RNA
    Àü´Þ RNA
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
host restriction-modification A bacterial system where the bacterium is able to destroy invading DNA from a bacteriophage (virus which infects bacteria) while at the same time preventing the destruction of their own DNA. The phage DNA is cleaved by a restriction enzyme made by the bacterium, the bacterial DNA is modified (usually with methylation) so that the enzyme will not destroy it.
(09 Oct 1997)
host-vector system A combination of a bacterial host cell (i.e. A specific strain) and a virus vector (i.e. A particular bacteriophage strain) which work well together for DNA cloning.
(09 Oct 1997)
host versus graft reaction The normal lymphocyte mediated reactions of a host against allogeneic or xenogeneic cells acquired as a graft or otherwise, which lead to damage or/and destruction of the grafted cells. The opposite of graft-versus-host reaction. The common basis of graft rejection.
(18 Nov 1997)
host vs graft reaction The immune responses of a host to a graft. A specific response is graft rejection.
(12 Dec 1998)
dead-end host A host from which infectious agents are not transmitted to other susceptible host's.
(05 Mar 2000)
definitive host <epidemiology> The host in which a parasite reproduces sexually.
(05 Dec 1998)
disease, graft-versus-host A reaction of donated bone marrow against a patient's own tissue. Also called GVHD.
(12 Dec 1998)
immunocompromised host A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
(12 Dec 1998)
intermediate host <epidemiology> See vector.
(05 Dec 1998)
transport host An intermediate host in which no development of the parasite occurs, although its presence may be required as an essential link in the completion of the parasite's life cycle; e.g., the successive fish host's that carry the plerocercoid of Diphyllobothrium latum, the broad fish tapeworm, to larger food fish eventually eaten by man or other final host's.
Synonym: transport host.
(05 Mar 2000)
type host <zoology> The host species with which the name-bearing type of a nominal species or subspecies was associated.
(09 Jan 1998)
final host <epidemiology> The host in which a parasite reproduces sexually.
(05 Dec 1998)
adoptive transfer Form of passive immunization where previously sensitised immunologic agents (cells or serum) are transferred to non-immune recipients. When transfer of cells is used as a therapy for the treatment of neoplasms, it is called adoptive immunotherapy (immunotherapy, adoptive).
(12 Dec 1998)
gamete intra-fallopian transfer <gynaecology> Gamete intra-fallopian transfer is a technique that involves combining eggs and sperm outside of the body and immediately placing them into the fallopian tubes to achieve fertilization.
A technique that came into use in the mid-1980's for assisted conception in infertile women with normal fallopian tubes. The protocol consists of hormonal stimulation of the ovaries, followed by laparoscopic follicular aspiration of oocytes, and then the transfer of sperm and oocytes by catheterization into the fallopian tubes.
Acronym: GIFT
(12 Dec 1998)
gel transfer Any lab technique used to transfer substances which had been separated using gel electrophoresis from the gel to a membrane for further processing or analysis. For example: any type of blotting.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • electronic transfer
    ÀüÀÚ½Ä ±ÝÀü Ãâ³³
  • embryo transfer
    (ÀÇ)¹èÀ̽Ä(Àڱà ³»ÀÇ Å¾Ƹ¦ ¿Ü°úÀû ¼ö´ÜÀ¸·Î ´Ù¸¥ ÀÚ±ÃÀ¸·Î ¿Å±â´Â °Í)
  • negative transfer
    ¼Ò±ØÀû ÀüÀÌ(ÇнÀ °úÁ¤¿¡¼­ ¼±Çà ÇнÀÀÌ ÈÄÀÇ ÇнÀÀ» ¹æÇØ ¾ïÁ¦
  • transfer
    Àüȯ;À̵¿;ÀüÇÐ;ÀüÀÓ;(±Ç¸®ÀÇ)ÀÌÀü;(¸íÀÇÀÇ)º¯°æ;´ëü;ȯ;°¥¾ÆÅ¸±â;°¥¾ÆÅ¸´Â Ç¥
  • transfer
    ¿Å´Ù;ÀüÀԵǴÙ;°¥¾ÆÅ¸´Ù
  • transfer
    ¿Å±â´Ù;³ª¸£´Ù;¾çµµÇÏ´Ù;Àü»çÇÏ´Ù;ÀüÀÓ½ÃŰ´Ù
  • transfer RNA
    ÀüÀÌ RNA;¿î¹Ý RNA
  • transfer company
    ±Ù°Å¸® ¿î¼Ûȸ»ç(µÎ Å͹̳Π¿ª ±¸°£ µî)
  • transfer table
    (Áö»ó½Ä)õÂ÷´ë
  • transfer tax
    »ó¼Ó¼¼;¾çµµ¼¼
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á